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Abstract
Background—Interleukin-1 plays a pivotal role in in the pathogenesis of systemic juvenile
idiopathic arthritis (sJIA). We assessed the efficacy and safety of rilonacept (IL-1 trap), an IL-1
inhibitor, in a randomized, double-blind, placebo-controlled trial.
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Methods—An initial 4-week double-blind placebo phase was incorporated into a 24-week
randomized multi-center design, followed by an open label phase. We randomized 71 children
with at least 2 active joints 1:1 to 2 arms of the study. Patients in the rilonacept arm received
rilonacept (4.4mg/kg loading dose followed by 2.2mg/kg weekly, subcutaneously) from day 0;
patients in the placebo arm received placebo for 4 weeks followed by a loading dose of rilonacept
at week 4 followed by weekly maintenance doses. The primary endpoint was time to response,
using adapted JIA ACR30 response criteria coupled with absence of fever and taper of systemic
corticosteroids using pre-specified criteria.
Results: Time to response was shorter in the rilonacept arm than in the placebo arm (Chi-square
7.235, P=.007). Secondary analysis showed 20/35 (57%) of patients in the rilonacept arm
responded at week 4 compared to 9/33 (27%) in the placebo arm (P=.016) using the same response
criteria. Exacerbation of sJIA (4) was the most common SAE. More patients in the rilonacept arm
had elevated liver transaminases, including more than three times the upper limits of normal, as
compared to those in the placebo arm. Adverse events were similar in the two arms of the study.
Conclusions—Rilonacept was generally well tolerated and demonstrated efficacy in active
sJIA.
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Systemic juvenile idiopathic arthritis (sJIA) is distinguished from other forms of JIA by its
distinctive systemic features at onset, including high spiking fever, characteristic rash,
hepatosplenomegaly, polyserositis, lymphadenopathy, anemia, leukocytosis and
thrombocytosis and rarely macrophage activation syndrome1. More than 50% of children
with sJIA have a polyphasic or chronic persistent disease course 2 and more than half suffer
poor outcomes 3 and seldom death4 in the absence of highly active biologic treatment.
Predictors of joint damage and poor functional outcome include young age at diagnosis,
longer disease duration, persistent systemic long-term corticosteroid therapy thrombocytosis
and high inflammatory markers 5,6.
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This randomized controlled trial was designed to determine the safety and effectiveness of
rilonacept in sJIA, and to confirm and extend findings from a number of anecdotal studies
and trials showing effectiveness of IL-1 inhibition7-15. Rilonacept is a fusion protein
consisting of human cytokine receptor extracellular domains of both receptor components
required for IL-1 signaling ( IL-1 Type I receptor and the IL-1 receptor accessory protein)
with the Fc portion of human IgG1. It binds IL-1α and IL-1β with picomolar affinity but
potentially can bind to IL-1 receptor antagonist16. Although the primary efficacy endpoint
was not met in a pilot, double-blind placebo-controlled study, rilonacept appeared to be well
tolerated and efficacious enabling corticosteroid dose reduction in the open label long-term
extension phase17.

Methods
Patients
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The study was conducted in compliance with principles of the International Conference on
Harmonization and Good Clinical Practice. The study was approved by the Institutional
Review Boards of each study site. All patients or parents/guardians provided written
informed consent. An independent Data Safety Monitoring Board, appointed by NIH/
NIAMS, met every 6 months to evaluate study conduct and safety. Twenty Childhood
Arthritis and Rheumatology Research Alliance (CARRA) centers in the US enrolled patients
from 11/2008 to 5/2012. Key Inclusion criteria included: International League against
Rheumatism criteria for sJIA 18; age ≥18 months to ≤19 years; ≥2 active joints; stable
methotrexate dose for ≥4 weeks; stable corticosteroids ≥2 weeks; ≤ 2mg/kg or 60mg
prednisone or equivalent. If previously treated with biologics, the following lengths of
discontinuation were required: anakinra ≥4 days, etanercept ≥4 weeks, adalimumab ≥6
weeks, tocilizumab ≥6 weeks, abatacept ≥6 weeks, and infliximab ≥8 weeks. Key exclusion
criteria included current treatment with disease modifying anti-rheumatic drug other than
methotrexate; intra-articular corticosteroids or pulse steroids within 4 weeks; leflunomide
without cholestyramine wash out; cyclophosphamide within 3 months; IVIG within 4
weeks; treatment in the past with an IL-1 inhibitor other than anakinra; renal insufficiency as
defined as an elevated serum creatinine; aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) > 2 times the upper limit of normal; thrombo-, leuko-, or neutropenia; prolonged PT or PTT; positive PPD without treatment documentation; live virus
vaccine within 1 month; pregnancy or sexual activity without contraception.
Arthritis Rheumatol. Author manuscript; available in PMC 2015 September 01.
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Study Design
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RAPPORT incorporated an initial 4-week double-blind placebo phase within a 24-week
randomized multi-center design. As such, patients were randomized 1:1 to treatment with (a)
4 weeks of placebo followed by 20 weeks of rilonacept or (b) 24 weeks of rilonacept,
resulting in a double-blind phase (weeks 0-4) and an all active treatment phase (weeks 4-24).
This was followed by an open label Long Term Extension (LTE) phase (24 weeks-21
months). The randomized placebo phase study design is based on the assumption that if
treatment is effective, patients who receive active drug earlier will respond sooner, on
average, than patients who receive active drug later 19. This design is especially useful when
testing highly effective therapies with rapid onset of action of several weeks, and when
minimizing time on placebo or safety issues are important 19. IL-1 inhibition appears to have
an onset of action of 2 weeks, based on data in sJIA subjects in the Amgen-sponsored study
of anakinra in polyarticular-JIA that included subjects with sJIA 12. Randomization was
performed using a Web-based randomization and drug supply management system (WebEZ,
Almac, Durham, North Carolina). The central randomization scheme used a fixed-block
size, stratified according to baseline corticosteroid use. Rilonacept and matching placebo
were provided by Regeneron Pharmaceuticals, Inc. (New York).
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In the rilonacept arm, a loading dose (4.4mg/kg, maximum dose 320mg) of rilonacept was
given on day 0 followed by weekly maintenance doses (2.2mg/kg, to a maximum dose
160mg). In the placebo arm, a loading dose of placebo was given on day 0 followed by 3
maintenance doses of placebo; then a loading dose of rilonacept was given on day 28
followed by weekly maintenance doses of rilonacept. Evaluation of efficacy occurred during
the first 12 weeks of the study; safety was assessed in the first 24 weeks and in the LTE. All
patients who benefited from rilonacept treatment as judged by the treating physician were
eligible for enrollment in the LTE phase. Patients in the LTE were initially offered open
label rilonacept for 2 years or until rilonacept was commercially available. These criteria
were shortened for some patients because of budgetary issues.
Clinical Assessments
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Screening visits could occur up to 4 weeks before randomization. A randomization/baseline
visit occurred at week 0 and follow up visits occurred at weeks 2, 4, 6, 8, 10, 12, 14, 18 (by
telephone), and 24. Patients were seen every 3 months in the LTE. The 2 week interval
between visits in the first 14 weeks was used to maximize the precision of estimation of time
to response. Medical history, physical examination, concomitant medications, adverse
events, fever (patients’ daily diary), blinded joint assessment, physician global assessment,
parent/guardian/patient global assessment, clinical laboratory tests, and Childhood Health
Assessment Questionnaire (CHAQ) were assessed at every (non-telephone) visit. Fasting
lipoprotein profiles and PedsQL questionnaires were assessed at week 0, 12 and 24.
Biospecimens (DNA, RNA, whole blood, serum, plasma) were obtained during the trial.
Endpoints
The primary endpoint was time to response during the 12 week efficacy period. Response
was defined as a composite of 1)improvement in the JIA ACR30 20, 2) absence of fever
≥38.5°C in the previous 2 weeks, and 3)at least 10% taper in systemic corticosteroids from
Arthritis Rheumatol. Author manuscript; available in PMC 2015 September 01.
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baseline if the patient were taking corticosteroids. The JIA ACR30 algorithm required at
least 30% improvement from baseline in at least 3 of 6 core variables, with no more than 1
variable worsening by 30% or more. Corticosteroids were required to be tapered if all of the
following criteria developed by consensus among the RAPPORT investigators 21 were met:
fever ≤2 days in previous 7 days, absence of poor physical function, and absence of
laboratory values associated with impending MAS. The time to response was defined as the
visit designation at which the patient first achieved the response criteria and maintained
response until the next scheduled visit. Absence of rash was not included in the response
criteria.
Corticosteroids were increased or started if one or more of the following criteria developed
by consensus of the RAPPORT investigators were met21: MAS 22, incomplete MAS,
symptomatic anemia with a hemoglobin ≤6.5g/dL, myocarditis, or symptomatic
pneumonitis, or serositis unresponsive to NSAIDs. Patients who met criteria for
corticosteroid increase/start were deemed non-responders. Patients who met the criteria for
non-response and started/increased corticosteroids were no longer eligible for response.
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Secondary endpoints included the JIA ACR30, 50, 70, inactive disease 23, presence of fever,
serositis, symptomatic anemia, abnormal liver function, rash, MAS, incomplete MAS,
corticosteroid dose, CHAQ, and PedsQL Generic Core Modules. Adverse events (AEs) and
Serious Adverse Events (SAEs) were collected throughout the study.
Data Analysis
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Planned enrollment was 100 patients (50 per arm) to achieve ≥80% power to detect a
difference at a 2-sided α level of 0.05. This sample size was determined based on the results
from multiple Monte-Carlo simulations conducted under various assumptions for
distribution of time to response in the two study arms.The trial was ended before reaching
the enrollment goal due to slow enrollment and financial considerations. One pre-specified
interim analysis of the primary endpoint to examine early stopping for overwhelming
efficacy was performed when data were available for 50 patients. The Lan-DeMets flexible
spending function corresponding to the O'Brian-Fleming stopping boundary was used to
preserve the overall type I error of 0.0524. The stopping boundary P value at the interim
analysis was 0.007. After reviewing the efficacy data at the interim analysis, the DSMB
recommended to continue the study. The 2-sided P value for rejecting the null hypothesis of
no difference between the treatment arms for the primary endpoint at the final analysis was
0.048. A 2-sided α level of 0.05 was considered statistically significant for all other
endpoints. P values for the secondary analyses were not adjusted for multiple comparisons.
All analyses were performed in SAS version 9.2 (SAS Institute Inc., Cary, NC).
Data were analyzed on an intent-to-treat basis. Descriptive statistics were summarized by
treatment arm. The primary endpoint analysis compared time to response between treatment
arms using Gehan-Wilcoxon test, which emphasizes early differences. Missing temperatures
were imputed as fever free when calculating the response endpoint. A sensitivity analysis
was performed treating the response endpoint as missing if the fever criterion could not be
determined due to missing temperatures. In both the primary and sensitivity analyses,
patients were censored if the response endpoint was missing at two consecutive visits, or if
Arthritis Rheumatol. Author manuscript; available in PMC 2015 September 01.
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the patient met criteria for non-response and started/ increased corticosteroids prior to
meeting the response criteria. Response rates were calculated using cumulative incidence
estimation, treating non-response as a competing event. Comparison of the response to
rilonacept vs. placebo at the end of the placebo phase (week 4) was evaluated using Fisher's
exact test. Logistic regression was used to adjust for sJIA duration and presence of articular
without systemic symptoms and to explore the association between those baseline
characteristics and response at week 4.
JIA ACR30, 50, and corticosteroid dose were analyzed using a generalized estimating
equation (GEE) repeated measures model. Improvement in JIA ACR70 was analyzed using
Fisher's exact test. Adverse events were compared using chi-square test. Infection rates were
compared using Poisson regression.

Results
Study Population
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Seventy-one patients were randomized (Figure 1). Baseline demographic and disease
characteristics were similar between the two arms of the study, except recent fever was more
common in the rilonacept group (Table 1). Fourteen patients withdrew from the study prior
to week 24: 8 for inadequate response (7 placebo arm, 1 rilonacept arm), 2 withdrew consent
(1 in each arm), 1 for a serious adverse event (elevated liver transaminases) in the rilonacept
arm, 1 excluded before drug exposure for not meeting inclusion/exclusion criteria, 2 lost to
follow up (1 in each arm). Of the 57 completers, 40 enrolled in the LTE; 29 completed the
LTE and 11 did not.
Efficacy
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The primary endpoint, time to response as defined by time to achieve the composite
endpoint of JIA ACR30, absence of fever, and corticosteroid tapering (for patients taking
corticosteroids), was shorter in the rilonacept arm (median 4 weeks; 25th, 75th percentiles
2,10 weeks) than in the placebo arm (median 8 weeks; 25th percentile 6 weeks, 75th
percentile not estimable from the data) (Figure 2; chi-square 7.235; P=0.007). By week 12,
27 of 35 patients (77%) receiving rilonacept continuously from onset of the trial and 20 of
34 patients (59%) receiving placebo for the initial 4 weeks, met the primary endpoint of
response. The sensitivity analysis of time to response without fever imputation also
demonstrated shorter time to response in the rilonacept arm as compared to the placebo arm
(chi-square = 5.270; P=0.022). Secondary endpoint analysis of the response rate at 4 weeks
showed 20 of 35 patients in the rilonacept arm compared to 9 of 33 patients in the placebo
arm (57% vs. 27%; P=0.016). The JIA ACR30, 50, and 70 response rates were significantly
better in the rilonacept arm at week 4 compared to the placebo arm (Table 2; all P<0.05).
Twenty-six of 35 (74%) patients in the rilonacept arm compared to 13 of 33 (39%) in the
placebo arm met JIA ACR30 response criteria at week 4 (OR=4.54; 95% CI 1.62, 12.72;
P=0.004); 21 of 35 (60%) vs. 10 of 33 (30%) in the placebo arm met JIA ACR50 (OR=3.50;
95% CI 1.28, 9.56; P=0.015); 14 of 35 (40%) vs. 4 of 33 (12%) met JIA ACR70 (P=0.013).
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A pre-specified logistic regression analysis adjusted for sJIA duration and presence of
articular involvement without systemic symptoms showed that the significant rilonacept
effect on response at week 4 persisted after adjustment (OR=3.42; 95% CI 1.21, 9.70;
P=0.020). We did not observe a statistically significant difference in odds of response at
week 4 for patients without systemic manifestations at baseline compared to patients with
systemic manifestations (OR=0.87; 95% CI 0.32, 2.40; P=0.794). There was no statistically
significant difference in odds of responding at week 4 as a function of longer sJIA duration
(OR=0.91; 95% CI 0.75, 1.11; P=0.359). No statistically significant difference in response
rates at week 4 was observed for 26 patients unexposed to anakinra (44%) compared to 24
patients previously exposed to anakinra (40%); 8 subjects had missing data regarding
anakinra exposure; 2 had missing response data at week 4.
Seventeen of the 50 patients taking corticosteroids at baseline discontinued corticosteroids
during the study. Overall, corticosteroid dose decreased more in the rilonacept arm than in
the placebo arm during the efficacy period (P=0.036; Figure 3). Laboratory tests reflecting
disease activity are reported by treatment arm in Table 2.
Safety
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In the double-blind and treatment phases, the rilonacept arm performed at least as well as the
placebo arm in terms of safety (Table 3). There was not a higher incidence of infection in
the rilonacept arm in either phase. Four patients, all in the rilonacept arm, developed
elevations in liver transaminases of ≥2 times the upper limit of normal; 2 patients developed
elevations ≥5 times the upper limit of normal (one of these was considered an SAE). There
were 14 SAEs: 9 among patients in the rilonacept arm and 5 in the placebo arm with the
most common being sJIA flare (4). The AST liver function test was consistently higher in
the rilonacept arm.

Discussion
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sJIA has proven to be more difficult to treat than other categories of JIA with poor response
to methotrexate and TNF inhibitors. This study demonstrates efficacy of rilonacept in active
sJIA and confirms the remarkable effectiveness of IL-1 inhibition in sJIA, which is now
demonstrated in 3 different IL-1 inhibitors, anakinra14, canakinumab10, rilonacept and in
one IL-6 inhibitor, tocilizumab25 . The long-term dependence on corticosteroid therapy for
many children with severe systemic manifestations has resulted in significant treatmentrelated comorbidities, and provided an important impetus to finding an effective nocorticosteroid treatment for sJIA. The remarkable clinical responsiveness to IL-1
inhibition 7-15 suggests that IL-1 plays a pivotal role in the pathogenesis of sJIA 7,26-28 and
the lack of HLA association, autoantibodies, and other classical features of autoimmune
diseases, suggest the sJIA should be reclassified as an autoinflammatory disease29.
This study utilized a novel design, the randomized placebo phase trial19 to meet several
objectives. First and foremost, we were concerned that the randomized withdrawal study
design which was so successful in other JIA trials30,31 might trigger a life threatening event
when rilonacept was abruptly withdrawn in responders. Secondly, our study design directly
tested corticosteroid tapering, by allowing inclusion of patients requiring high doses of
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corticosteroids, and incorporating a forced corticosteroid taper into the primary endpoint.
Lastly, the placebo phase occurring at the beginning of the trial allowed collection of
biospecimens for studying the effects of an IL-1 inhibitor on the immunobiology of sJIA in
the context of highly curated clinical data. Currently, 4 translational studies are underway.
Previous observational studies suggest that sJIA patients without systemic manifestations,
and/or longer disease duration have poorer responses to IL-1 inhibition11,32. We did not
observe a statistically significant association between response at week 4 and those patient
characteristics in our study population. However, a trend was noted with regard to duration
of disease: the median disease duration was shorter among patients who responded at week
4 compared to those who didn't (9.6 vs. 15.3 months).
Rilonacept had an acceptable safety profile in this study. There were no opportunistic
infections, however elevation in liver transaminases in at least one patient was clearly
caused by rilonacept as the adverse event recurred on re-challenge. There was only one
episode of MAS which was triggered by EBV infection during the LTE.
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Recently, another IL-1 inhibitor – canakinumab – was shown to be effective in treating sJIA
patients with systemic symptoms in two separate double-blind, placebo-controlled studies
and has been FDA approved for sJIA10. Rilonacept could offer an alternative with its
circulating half-life of 8.6 days33 in contrast to the long biologic activity of canakinumab
(236 days) which could be a disadvantage in the setting of an SAE. The weekly
administration of rilonacept may be preferred by families over anakinra which must be given
by painful daily subcutaneous injections14. In contrast to all the IL-1 inhibitors tocilizumab,
an IL-6 inhibitor which has also been shown to be effective in a double-blind, placebo
controlled trial, and is approved by the FDA for sJIA, is given by infusion25.
Limitations of the study were missing data regarding prior anakinra exposure, difficulty in
comparing adverse events between the two arms of the study because of the short placebo
phase and not meeting our enrollment goals by the time the study was discontinued by the
NIH/NIAMS.
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In summary, rilonacept was generally well tolerated and demonstrated efficacy in active
sJIA in our study. Rilonacept treatment facilitated corticosteroid tapering similarly to
tocilizumab and canakinumab. In addition, the ability to integrate clinical data and
biospecimens associated with this study will likely lead to advances in our understanding of
this unique and challenging disease.
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Figure 1. Flow of Patients in RAPPORT Trial

RAPPORT, The RAndomized Placebo Phase Study Of Rilonacept in the Treatment of
Systemic Juvenile Idiopathic Arthritis.
a Indicates patients who attended the week 24 study visit.
b Indicates patients who remained in long term extension until the LTE period ended.
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Figure 2. Cumulative Incidence Estimates of Response by Treatment Arm

The cumulative incidence curve shows a higher rate of response in the rilonacept arm
compared to the placebo arm. The primary endpoint of response was assessed at bi-weekly
study visits during the efficacy period. Response was defined as improvement in the
American College of Rheumatology (ACR) Pediatric 30, absence of fevers ≥38.5°C in the
previous 2 weeks, and at least 10% taper in systemic corticosteroids from baseline. Missing
temperatures were imputed as fever free. Patients were no longer eligible for the primary
endpoint if corticosteroids were increased or started based on the non-response algorithm
prior to meeting the criteria for response. The cumulative incidence estimation treated nonresponse as a competing event. The number of patients at risk displayed below the figure
shows the number of patients eligible to meet the response designation for the first time at
each study week.
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Figure 3. Change Over Time in Corticosteroid Dose

Panel A shows the median corticosteroid dose by treatment group during the efficacy period,
with I bars representing interquartile range. Panel B shows the median corticosteroid dose
aggregated for all patients during the follow-up safety period, with I bars representing
interquartile range. Patients’ oral dose at their last visit during the long term extension phase
is displayed. The median time on study at the last visit was 16 months, with a range of 8 to
26 months.
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Baseline Demographics and Disease Characteristics of Study Patients
Characteristic

Rilonacept (N=36)

Placebo (N=35)

13 (36)

12 (34)

23 (64)

23 (66)

Sex–no. (%)
    Male
    Female
a

Race–no. (%)
    Black

5 (14)

7 (20)

    White

25 (69)

23 (66)

6 (17)

5 (14)

b

    Other

c

Ethnicity–no. (%)
    Hispanic

7 (19)

5 (14)

    Non–Hispanic

29 (81)

30 (86)

9.5 (4.6)

10.5 (4.4)

9.5 (6.0,13.0)

11.0 (6.0,14.0)

2.6 (3.6)

2.6 (3.1)

0.7 (0.2, 4.0)

1.4 (0.4, 3.6)

Age–yr
    Mean (SD)

NIH-PA Author Manuscript

    Median (25th,75th)
Disease duration–yr
    Mean(SD)
    Median (25th,75th)
Number of active joints
    Mean(SD)

11.7 (9.6)

10.5 (7.6)

7.5 (4.0, 16.0)

9.0 (5.0, 15.0)

Fever past 7 days–no. (%)

10 (28)

6 (17.1)

Articular without systemic symptoms–no. (%)

16 (44)

16 (46)

    Corticosteroids

30 (83)

33 (94)

    Methotrexate

21 (58)

26 (74)

    Median (25th,75th)

Prior medication use –no. (%)

NIH-PA Author Manuscript

    Leflunomide

1 (3)

2 (6)

    Infliximab

5 (14)

6 (17)

    Etanercept

12 (33)

16 (46)

    Abatacept

5 (14)

4 (11)

d

13 (36)

13 (37)

Baseline medication use–no. (%)

30 (83)

33 (94)

e
    Corticosteroid

25 (69)

22 (63)

.38(.23,.55)

.37(.19,.66)

16 (44)

19 (54)

    Incomplete MAS

1 (3)

3 (9)

    Complete MAS

1 (3)

1 (3)

    Serositis

9 (25)

8 (23)

    Anakinra

f

    Corticosteroid dose
    Methotrexate

Characteristics in the past–no. (%)
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Characteristic
    sJIA rash

Page 15

Rilonacept (N=36)

Placebo (N=35)

32 (89)

33 (94)

NIH-PA Author Manuscript

a

Race was collected via self-report . Categories consisted of American Indian/Alaska Native, Asian, black/African American, Native Hawaiian/
other Pacific Islander, and white.
b

Other includes patients who self-identified as Asian, Native Hawaiian/other Pacific Islander, and multiracial. It also includes 3 patients where race
was not reported.
c

Ethnicity was collected via self-report. Categories consisted of Hispanic/Latino and non-Hispanic/Latino.

d

Anakinra exposure data were missing in 8 subjects; 4 in each arm.

e

Corticosteroid includes oral, intravenous, and intramuscular steroids.

f

Median and inter quartile ranges prednisone equivalents mg/kg/d
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b,e

f

JIA ACR 70 response

Arthritis Rheumatol. Author manuscript; available in PMC 2015 September 01.

    CHAQ-DI score

        Median % change from baseline

        Interquartile range

        Median

h
    Score for parent's global assessment of overall well-being

        Median % change from baseline

        Interquartile range

        Median

    Score for physician's global assessment of disease activity

        Median % change from baseline

        Interquartile range

        Median

    No. of joints with limited range of motion

        Median % change from baseline

        Interquartile range

        Median

    No. of joints with active arthritis

JIA ACR core set of variables

Inactive disease

g

--

b,d

JIA ACR 50 response

--

33.0-65.0

49.5

26.0-65.0

43.0

--

2.0-10.5

4.0

4.0-16.0

7.5

--

--

15/36 (42%)

10/36 (28%)

Rilonacept

b,c

JIA ACR 30 response

    Rash

    Fever

a

Systemic features

Variable

--

28.0-68.0

53.0

49.0-68.0

59.5

--

2.0-11.0

8.0

5.0-15.0

9.0

--

--

--

--

15/35 (43%)

6/35 (17%)

Placebo

Baseline

60.8

3.0-23.0

12.0

73.7

3.0-34.0

12.5

50.0

0.0-6.5

2.0

70.0

1.0-7.5

3.0

2/36 (6%)

14/35 (40%)

21/35 (60%)

26/35 (74%)

3/36 (8%)

3/36 (8%)

Rilonacept

6.2

15.0-67.0

34.0

27.9

25.0-65.0

40.5

0.0

2.0-12.0

8.0

12.5

4.0-17.0

7.0

0/34

4/33 (12%)

10/33 (30%)

13/33 (39%)

8/34 (24%)

5/34 (15%)

Placebo

Week 4

NIH-PA Author Manuscript

Change over time in Systemic Features, ACR Variables, and Laboratory Values

81.5

0.0-17.0

3.5

81.7

2.0-19.0

10.0

75.0

0.0-8.0

1.0

81.3

0.0-5.0

2.0

4/33 (12%)

23/33 (70%)

28/33 (85%)

29/33 (88%)

3/33 (9%)

4/33 (12%)

Rilonacept

66.7

2.0-38.0

8.0

73.1

5.0-30.0

18.0

47.7

0.0-9.0

2.0

63.6

0.0-10.0

4.0

3/29 (10%)

17/29 (59%)

19/29 (66%)

22/29 (76%)

1/29 (3%)

1/29 (3%)

Placebo

Week 12

79.4

1.0-29.0

7.0

85.8

1.0-33.0

6.0

66.7

0.0-7.0

1.0

90.0

0.0-7.0

1.0

11/55 (20%)

35/55 (64%)

43/55 (78%)

45/55 (82%)

4/57 (7%)

--

Rilonacept

Week 24
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        Median

    ESR (mm/hr)

q

        Interquartile range

        Median

    Ferritin (ng/mL)

j,p

        Interquartile range

        Median

    Fibrinogen (mg/dL)

o

        Interquartile range

        Median

    D-dimer (ug/mL)

j,n

        Interquartile range

        Median

    Platelet count (×109/L)

        Interquartile range

        Median

m

    Total neutrophils (×109/L)

        Interquartile range

        Median

    Hemoglobin (g/dL)

Laboratory variables

l

        Median % change from baseline

        Interquartile range

        Median

i
    C-reactive protein (mg/dL)

        Median % change from baseline

        Interquartile range

        Median

Variable

NIH-PA Author Manuscript
40.0

52.5-291.0

112.0

283.0-532.0

361.0

0.36-3.66

1.38

352.0-534.0

449.0

5.43-19.07

9.76

10.3-11.9

11.0

--

0.40-9.15

4.40

--

0.75-1.63

1.00

Rilonacept

47.0

37.0-207.0

80.0

308.0-487.0

361.0

0.30-3.05

1.63

274.0-457.0

357.0

5.69-12.06

7.65

9.8-12.5

11.8

--

0.80-7.23

4.48

--

0.50-1.63

1.25

Placebo

12.0

13.0-68.0

29.0

228.0-329.0

243.5

0.34-1.58

0.52

279.0-400.0

341.0

3.07-8.48

5.46

10.9-12.6

11.8

52.4

0.40-1.85

0.40

34.5

0.00-1.13

0.43

Rilonacept

37.0

25.5-181.5

52.5

272.0-487.0

365.0

0.32-3.59

1.31

306.5-546.0

376.0

6.69-13.14

8.71

9.6-12.4

11.2

0.0

0.87-8.14

4.12

16.7

0.38-1.63

0.88

Placebo

Week 4

11.0

11.0-44.0

24.0

211.5-292.0

231.0

0.25-0.98

0.37

276.5-376.5

315.0

2.36-6.16

4.20

11.4-13.2

12.0

72.6

0.40-0.92

0.40

50.0

0.00-0.88

0.25

Rilonacept

15.5

8.0-36.0

20.0

217.0-334.0

258.0

0.23-1.86

0.59

275.0-389.0

338.0

3.51-6.24

4.83

11.0-12.4

11.6

50.0

0.40-2.29

0.40

59.4

0.00-1.25

0.25

Placebo

Week 12

10.5

--

213.0-360.5

257.0

--

277.0-409.0

312.0

2.27-5.74

3.94

11.2-13.0

12.1

50.0

0.40-1.95

0.40

80.0

0.00-1.00

0.13

Rilonacept

Week 24
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Baseline
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3.7-4.4

3.8-4.4

4.1

21.0-67.0

Placebo

4.2-4.4

4.4

7.0-28.0

Rilonacept

3.8-4.2

4.1

15.0-70.0

Placebo

4.3-4.6

4.2-4.6

4.3

8.0-29.0

4.1-4.6

4.4

6.0-22.0

Rilonacept

Week 24
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The normal range for ESR varied by site

q

The normal range for ferritin was 10-143ng/ml

The normal range for fibrinogen was 200-400mg/dl

p

o

n
The normal range for D-dimer was <0.499ug/ml

The normal range for platelets was 130-400 X 109/L

m

The normal range for total neutrophils was 1.8-8.0 X 109/L

The normal range for Hgb was 11.5-13.5g/dL

D-dimer and ferritin were not tested at week 24.

k

l

Parent's global assessment was based on a 100-mm visual-analogue scale. Score ranged from 0 (not active) to 100 (very active).

The normal range for C-reactive protein was 0 to 0.90 mg/dL.

j

i

h

Physician's global assessment was based on a 100-mm visual-analogue scale. Score ranged from 0 (very well) to 100 (very poor).

g

f
Inactive disease was defined as the following: absence of joints with active arthritis, fever, rash, serositis, splenomegaly, or generalized lymphadenopathy; normal erythrocyte sedimentation rate or Creactive protein; and score ≤1 for physician's global assessment of disease activity.

The JIA ACR70 algorithm required at least 70% improvement from baseline in at least 3 of 6 core variables, with no more than 1 variable worsening by 70% or more.

e

The JIA ACR50 algorithm required at least 50% improvement from baseline in at least 3 of 6 core variables, with no more than 1 variable worsening by 50% or more.

The JIA ACR30 algorithm required at least 30% improvement from baseline in at least 3 of 6 core variables, with no more than 1 variable worsening by 30% or more.

d

c

The core variables for ACR Pediatric response included number of joints with active arthritis, number of joints with limited range of motion, score for physician's global assessment of disease activity,
score for parent's global assessment of overall well-being, CHAQ-DI score, and C-reactive protein value. Absence of fever was not included.

b

Fever was assessed 7 days prior to baseline based on self-report. Fever (>=38.5° C) was assessed 14 days prior to Week 4 and Week 12 based on patient diaries. Days with missing temperature data were
imputed as “fever free.” Fever data was not collected at Week 24.

a

4.4

7.0-15.0

Placebo

Week 12
Rilonacept

Abbreviations: ACR, American College of Rheumatology; CHAQ-DI, Childhood Health Assessment Questionnaire–Disability Index

        Interquartile range

        Median

    Albumin (g/dL)
4.1

14.0-69.0

        Interquartile range

r

Rilonacept

NIH-PA Author Manuscript

Variable

Week 4

NIH-PA Author Manuscript

Baseline
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r
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The normal range for albumin was 3.2-5.0g/dl
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Adverse Events
Double-Blind Phase (0-4 weeks)

Variable

Treatment Phase (4-24 weeks)

LTE Open-Label
Phase (24 weeks
-21 months)

Rilonacept (N=36)

Placebo (N=35)

Rilonacept (N=35)

Placebo (N=33)

Rilonacept (N=40)

17

63

81

123

110

Adverse event
    No. of events
    No. of events per patient-year

6.1

23.9

6.2

11.3

3.0

10 (28%)

19 (54%)

27 (77%)

28 (85%)

28 (70%)

1 (3%)

2 (6%)

3 (9%)

1 (3%)

0

        Arthralgia

0

1 (3%)

2 (6%)

6 (18%)

1 (3%)

        Cough

0

1 (3%)

2 (6%)

3 (9%)

2 (5%)

    Patients with an event - no. (%)
    Most frequently reported events a
no. of patients (%)
        Abdominal pain upper

        Headache

NIH-PA Author Manuscript

1 (3%)

6 (17%)

1 (3%)

4 (12%)

3 (8%)

        Nausea

0

1 (3%)

1 (3%)

2 (6%)

3 (8%)

        Pharyngitis streptococcal

0

0

2 (6%)

2 (6%)

4 (10%)

        Pyrexia

0

1 (3%)

5 (14%)

1 (3%)

1 (3%)

2 (6%)

1 (3%)

1 (3%)

3 (9%)

1 (3%)

0

1 (3%)

5 (14%)

9 (27%)

2 (5%)

1 (3%)

2 (6%)

1 (3%)

2 (6%)

4 (10%)

        Rash
        Upper respiratory tract
infection
        Vomiting
Serious adverse events (SAE)
    No. of events

1

1

3

1

8

0.4

0.4

0.2

0.1

0.2

1 (3%)

1 (3%)

3 (9%)

1 (3%)

6 (15%)

0

0

0

0

1 (3%)

0

0

0

0

1 (3%)

1 (3%)

1 (3%)

0

1 (3%)

1 (3%)

0

0

1 (3%)

0

0

        Mental status changes

0

0

0

0

1 (3%)

        Pericarditis

0

0

0

0

1 (3%)

0

0

0

0

1 (3%)

        Pyrexia

0

0

1 (3%)

0

0

        Varicella

0

0

1 (3%)

0

0

        Viral upper respiratory tract
infection

0

0

0

0

1 (3%)

2

2

25

29

37

0.7

0.8

1.9

2.7

1.0

    No. of events per patient-year
    Patients with an event - no. (%)
    All reported events - no. of
patients (%)
        Gastroenteritis salmonella
        Histiocytosis haematophagic

b

c
        Juvenile arthritis

NIH-PA Author Manuscript

d

        Liver function test abnormal

        Pharyngitis streptococcal

e

Infection
    No. of events
    No. of events per patient-year
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Double-Blind Phase (0-4 weeks)

NIH-PA Author Manuscript

Variable
    Patients with an event - no. (%)

Treatment Phase (4-24 weeks)

LTE Open-Label
Phase (24 weeks
-21 months)

Rilonacept (N=36)

Placebo (N=35)

Rilonacept (N=35)

Placebo (N=33)

Rilonacept (N=40)

2 (6%)

2 (6%)

16 (46%)

20 (61%)

14 (35%)

a

The most frequently reported events were defined as events that occurred in at least 10% of all patients during the entire study.

b
One patient developed EBV triggered macrophage activation syndrome (proven by polymerase chain reaction testing) deemed an SAE during the
LTE phase.
c
The juvenile arthritis SAE summarized in the rilonacept arm during the double-blind phase was a pre-treatment event. The onset date occurred
after consent but prior to randomization.
d

One patient had elevations in the liver function tests deemed an SAE during the treatment phase. The elevations subsided when drug was
temporarily discontinued but recurred on re-challenge.
e

One patient had two separate episodes of streptococcal pharyngitis deemed SAEs during the LTE phase.
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